Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers

Deanna M. Barch, Cameron S Carter

Research output: Contribution to journalArticle

136 Citations (Scopus)

Abstract

Background: Recent research on schizophrenia indicates that cognitive deficits in this illness are important predictors of functional outcome, highlighting the need for treatments that have a positive impact on cognitive function. Here we explore the hypothesis that acute administration of D-amphetamine can improve cognitive function in individuals with schizophrenia who are well-treated with typical antipsychotics, as well as in healthy controls performing under dual task conditions designed to elicit performance deficits analogous to those found in schizophrenia. Methods: Ten individuals with schizophrenia taking haldol or prolixin and 22 healthy controls performed spatial working memory, language production, and Stroop tasks under both placebo and 0.25 mg/kg of D-amphetamine. Results: D-Amphetamine improved reactions times on the spatial working memory and Stroop tasks for both individuals with schizophrenia and controls, and improved working memory accuracy in schizophrenia. In addition, D-amphetamine improved language production for both individuals with schizophrenia and controls. Conclusions: These results provide support for the hypothesis that the adjunctive administration of dopamine agonist can improve cognitive in individuals with schizophrenia taking typical antipsychotics. The results are discussed in terms of their implications for understanding the nature of working memory deficits in schizophrenia, and potential future avenues for cognitive enhancement in this illness.

Original languageEnglish (US)
Pages (from-to)43-58
Number of pages16
JournalSchizophrenia Research
Volume77
Issue number1
DOIs
StatePublished - Sep 1 2005

Fingerprint

Amphetamine
Cognition
Schizophrenia
Healthy Volunteers
Short-Term Memory
Antipsychotic Agents
Language
Fluphenazine
Dopamine Agonists
Memory Disorders
Haloperidol
Reaction Time
Placebos
Research

Keywords

  • Amphetamine
  • Language production
  • Schizophrenia
  • Selective attention
  • Working memory

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Behavioral Neuroscience
  • Biological Psychiatry
  • Neurology
  • Psychology(all)

Cite this

Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. / Barch, Deanna M.; Carter, Cameron S.

In: Schizophrenia Research, Vol. 77, No. 1, 01.09.2005, p. 43-58.

Research output: Contribution to journalArticle

@article{94e1a319c646419a8ad8a0e8aee992e6,
title = "Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers",
abstract = "Background: Recent research on schizophrenia indicates that cognitive deficits in this illness are important predictors of functional outcome, highlighting the need for treatments that have a positive impact on cognitive function. Here we explore the hypothesis that acute administration of D-amphetamine can improve cognitive function in individuals with schizophrenia who are well-treated with typical antipsychotics, as well as in healthy controls performing under dual task conditions designed to elicit performance deficits analogous to those found in schizophrenia. Methods: Ten individuals with schizophrenia taking haldol or prolixin and 22 healthy controls performed spatial working memory, language production, and Stroop tasks under both placebo and 0.25 mg/kg of D-amphetamine. Results: D-Amphetamine improved reactions times on the spatial working memory and Stroop tasks for both individuals with schizophrenia and controls, and improved working memory accuracy in schizophrenia. In addition, D-amphetamine improved language production for both individuals with schizophrenia and controls. Conclusions: These results provide support for the hypothesis that the adjunctive administration of dopamine agonist can improve cognitive in individuals with schizophrenia taking typical antipsychotics. The results are discussed in terms of their implications for understanding the nature of working memory deficits in schizophrenia, and potential future avenues for cognitive enhancement in this illness.",
keywords = "Amphetamine, Language production, Schizophrenia, Selective attention, Working memory",
author = "Barch, {Deanna M.} and Carter, {Cameron S}",
year = "2005",
month = "9",
day = "1",
doi = "10.1016/j.schres.2004.12.019",
language = "English (US)",
volume = "77",
pages = "43--58",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers

AU - Barch, Deanna M.

AU - Carter, Cameron S

PY - 2005/9/1

Y1 - 2005/9/1

N2 - Background: Recent research on schizophrenia indicates that cognitive deficits in this illness are important predictors of functional outcome, highlighting the need for treatments that have a positive impact on cognitive function. Here we explore the hypothesis that acute administration of D-amphetamine can improve cognitive function in individuals with schizophrenia who are well-treated with typical antipsychotics, as well as in healthy controls performing under dual task conditions designed to elicit performance deficits analogous to those found in schizophrenia. Methods: Ten individuals with schizophrenia taking haldol or prolixin and 22 healthy controls performed spatial working memory, language production, and Stroop tasks under both placebo and 0.25 mg/kg of D-amphetamine. Results: D-Amphetamine improved reactions times on the spatial working memory and Stroop tasks for both individuals with schizophrenia and controls, and improved working memory accuracy in schizophrenia. In addition, D-amphetamine improved language production for both individuals with schizophrenia and controls. Conclusions: These results provide support for the hypothesis that the adjunctive administration of dopamine agonist can improve cognitive in individuals with schizophrenia taking typical antipsychotics. The results are discussed in terms of their implications for understanding the nature of working memory deficits in schizophrenia, and potential future avenues for cognitive enhancement in this illness.

AB - Background: Recent research on schizophrenia indicates that cognitive deficits in this illness are important predictors of functional outcome, highlighting the need for treatments that have a positive impact on cognitive function. Here we explore the hypothesis that acute administration of D-amphetamine can improve cognitive function in individuals with schizophrenia who are well-treated with typical antipsychotics, as well as in healthy controls performing under dual task conditions designed to elicit performance deficits analogous to those found in schizophrenia. Methods: Ten individuals with schizophrenia taking haldol or prolixin and 22 healthy controls performed spatial working memory, language production, and Stroop tasks under both placebo and 0.25 mg/kg of D-amphetamine. Results: D-Amphetamine improved reactions times on the spatial working memory and Stroop tasks for both individuals with schizophrenia and controls, and improved working memory accuracy in schizophrenia. In addition, D-amphetamine improved language production for both individuals with schizophrenia and controls. Conclusions: These results provide support for the hypothesis that the adjunctive administration of dopamine agonist can improve cognitive in individuals with schizophrenia taking typical antipsychotics. The results are discussed in terms of their implications for understanding the nature of working memory deficits in schizophrenia, and potential future avenues for cognitive enhancement in this illness.

KW - Amphetamine

KW - Language production

KW - Schizophrenia

KW - Selective attention

KW - Working memory

UR - http://www.scopus.com/inward/record.url?scp=21844469260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21844469260&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2004.12.019

DO - 10.1016/j.schres.2004.12.019

M3 - Article

C2 - 16005384

AN - SCOPUS:21844469260

VL - 77

SP - 43

EP - 58

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 1

ER -